{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:04:01Z","timestamp":1794953041604,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Huntington\u2019s Disease (HD) is a progressive neurodegenerative disorder caused by CAG trinucleotide repeat expansions in exon 1 of the huntingtin (\n                    <jats:italic>HTT<\/jats:italic>\n                    ) gene. The mutant HTT (mHTT) protein causes neuronal dysfunction, causing progressive motor, cognitive and behavioral abnormalities. Current treatments for HD only alleviate symptoms, but cerebral spinal fluid (CSF) or central nervous system (CNS) delivery of antisense oligonucleotides (ASOs) or virus vectors expressing RNA-induced silencing (RNAi) moieties designed to induce mHTT mRNA lowering have progressed to clinical trials. Here, we present an alternative disease modifying therapy the orally available, brain penetrant small molecule branaplam. By promoting inclusion of a pseudoexon in the primary transcript, branaplam lowers mHTT protein levels in HD patient cells, in an HD mouse model and in blood samples from Spinal Muscular Atrophy (SMA) Type I patients dosed orally for SMA (NCT02268552). Our work paves the way for evaluating branaplam\u2019s utility as an\u00a0 HD therapy, leveraging small molecule splicing modulators to reduce expression of dominant disease genes by driving pseudoexon inclusion.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-28653-6","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T06:05:35Z","timestamp":1646287535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9459-6076","authenticated-orcid":false,"given":"Caroline Gubser","family":"Keller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngah","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Mas","family":"Monteys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Beibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Teider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Faller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2448-9202","authenticated-orcid":false,"given":"Sophie","family":"St-Cyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Knehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Roma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6039-2518","authenticated-orcid":false,"given":"Marc","family":"Hild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitriy","family":"Lukashev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diethilde","family":"Theil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2369-7221","authenticated-orcid":false,"given":"Natalie","family":"Dales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang-Ho","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Borowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Dolmetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3715-6290","authenticated-orcid":false,"given":"Beverly L.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3917-0181","authenticated-orcid":false,"given":"Rajeev","family":"Sivasankaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"28653_CR1","doi-asserted-by":"crossref","unstructured":"MacDonald, M.E. et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell 72, 971\u2013983 (1993).","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"28653_CR2","first-page":"325","volume":"2","author":"GC Melkani","year":"2016","unstructured":"Melkani, G. C. Huntington\u2019s disease-induced cardiac disorders affect multiple cellular pathways. React. Oxyg. Species (Apex) 2, 325\u2013338 (2016).","journal-title":"React. Oxyg. Species (Apex)"},{"key":"28653_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1172\/JCI45691","volume":"121","author":"F Mochel","year":"2011","unstructured":"Mochel, F. & Haller, R. G. Energy deficit in Huntington disease: why it matters. J. Clin. Invest. 121, 493\u2013499 (2011).","journal-title":"J. Clin. Invest."},{"key":"28653_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/hum.2013.200","volume":"25","author":"LM Stanek","year":"2014","unstructured":"Stanek, L. M. et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease. Hum. Gene. Ther. 25, 461\u2013474 (2014).","journal-title":"Hum. Gene. Ther."},{"key":"28653_CR5","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz, H. B. et al. Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron 74, 1031\u20131044 (2012).","journal-title":"Neuron"},{"key":"28653_CR6","doi-asserted-by":"publisher","first-page":"eaar3959","DOI":"10.1126\/scitranslmed.aar3959","volume":"10","author":"AL Southwell","year":"2018","unstructured":"Southwell, A. L. et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease. Sci. Transl. Med. 10, eaar3959 (2018).","journal-title":"Sci. Transl. Med."},{"key":"28653_CR7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","volume":"16","author":"EJ Wild","year":"2017","unstructured":"Wild, E. J. & Tabrizi, S. J. Therapies targeting DNA and RNA in Huntington\u2019s disease. Lancet Neurol. 16, 837\u2013847 (2017).","journal-title":"Lancet Neurol."},{"key":"28653_CR8","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper, S. Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. Proc. Natl Acad. Sci. USA 102, 5820\u20135825 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"28653_CR9","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1073\/pnas.0801775105","volume":"105","author":"JL McBride","year":"2008","unstructured":"McBride, J. L. et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl Acad. Sci. USA 105, 5868\u20135873 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"28653_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nchembio.1837","volume":"11","author":"J Palacino","year":"2015","unstructured":"Palacino, J. et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat. Chem. Biol. 11, 511\u2013517 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"28653_CR11","unstructured":"Novartis Pharmaceuticals. An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02268552 (National Institute of Health, U.S. National Library of Medicine, 2020)."},{"key":"28653_CR12","doi-asserted-by":"publisher","first-page":"a003707","DOI":"10.1101\/cshperspect.a003707","volume":"3","author":"CL Will","year":"2011","unstructured":"Will, C. L. & L\u00fchrmann, R. Spliceosome structure and function. Cold Spring Harb. Perspect. Biol. 3, a003707 (2011).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"28653_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/0471250953.bi1114s51","volume":"51","author":"A Dobin","year":"2015","unstructured":"Dobin, A. & Gingeras, T. R. Mapping RNA-seq reads with STAR. Curr. Protoc. Bioinforma. 51, 11\u201319 (2015).","journal-title":"Curr. Protoc. Bioinforma."},{"key":"28653_CR14","doi-asserted-by":"crossref","unstructured":"Sun, H. & Chasin, L. A. Multiple splicing defects in an intronic false exon. Mol. Cell Biol. 20, 6414\u20136425 (2000).","DOI":"10.1128\/MCB.20.17.6414-6425.2000"},{"key":"28653_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-021-03770-2","volume":"596","author":"AM Monteys","year":"2021","unstructured":"Monteys, A. M. et al. Regulated control of gene therapies by drug-induced splicing. Nature 596, 291\u2013295 (2021).","journal-title":"Nature"},{"key":"28653_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1118-6","volume":"17","author":"A Nellore","year":"2016","unstructured":"Nellore, A. et al. Human splicing diversity and the extent of unannotated splice junctions across human RNA-seq samples on the sequence read archive. Genome Biol. 17, 266 (2016).","journal-title":"Genome Biol."},{"key":"28653_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/bioinformatics\/btx547","volume":"34","author":"C Wilks","year":"2018","unstructured":"Wilks, C., Gaddipati, P., Nellore, A. & Langmead, B. Snaptron: querying splicing patterns across tens of thousands of RNA-seq samples. Bioinformatics 34, 114\u2013116 (2018).","journal-title":"Bioinformatics"},{"key":"28653_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434\u2013443 (2020).","journal-title":"Nature"},{"key":"28653_CR19","doi-asserted-by":"publisher","first-page":"e124403","DOI":"10.1172\/jci.insight.124403","volume":"4","author":"V Bolduc","year":"2019","unstructured":"Bolduc, V. et al. A recurrent COL6A1 pseudoexon insertion causes muscular dystrophy and is effectively targeted by splice-correction therapies. JCI Insight 4, e124403 (2019).","journal-title":"JCI Insight"},{"key":"28653_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-019-1646-9","volume":"574","author":"D Inoue","year":"2019","unstructured":"Inoue, D. et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature 574, 432\u2013436 (2019).","journal-title":"Nature"},{"key":"28653_CR21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ajhg.2018.10.023","volume":"103","author":"GL Carvill","year":"2018","unstructured":"Carvill, G. L. et al. Aberrant inclusion of a poison exon causes Dravet syndrome and related SCN1A-associated genetic epilepsies. Am. J. Hum. Genet. 103, 1022\u20131029 (2018).","journal-title":"Am. J. Hum. Genet."},{"key":"28653_CR22","doi-asserted-by":"publisher","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","volume":"28","author":"M Gray","year":"2008","unstructured":"Gray, M. et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28, 6182\u20136195 (2008).","journal-title":"J. Neurosci."},{"key":"28653_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-1-4939-7825-0_7","volume":"1780","author":"SB Dunnett","year":"2018","unstructured":"Dunnett, S. B. & Brooks, S. P. Motor assessment in Huntington\u2019s disease mice. Methods Mol. Biol. 1780, 121\u2013141 (2018).","journal-title":"Methods Mol. Biol."},{"key":"28653_CR24","doi-asserted-by":"publisher","first-page":"8989","DOI":"10.1523\/JNEUROSCI.1830-07.2007","volume":"27","author":"MY Heng","year":"2007","unstructured":"Heng, M. Y., Tallaksen-Greene, S. J., Detloff, P. J. & Albin, R. L. Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington\u2019s disease. J. Neurosci. 27, 8989\u20138998 (2007).","journal-title":"J. Neurosci."},{"key":"28653_CR25","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/hmg\/ddw050","volume":"25","author":"S Mantovani","year":"2016","unstructured":"Mantovani, S. et al. Motor deficits associated with Huntington\u2019s disease occur in the absence of striatal degeneration in BACHD transgenic mice. Hum. Mol. Genet 25, 1780\u20131791 (2016).","journal-title":"Hum. Mol. Genet"},{"key":"28653_CR26","doi-asserted-by":"publisher","unstructured":"St-Cyr, S., Smith, A. R. & Davidson, B. L., Temporal phenotypic changes in Huntington\u2019s disease models for preclinical studies. J. Huntington\u2019s Dis. https:\/\/doi.org\/10.3233\/JHD-210515 (2022). (in press).","DOI":"10.3233\/JHD-210515"},{"key":"28653_CR27","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/hmg\/ddi147","volume":"14","author":"JM Van Raamsdonk","year":"2005","unstructured":"Van Raamsdonk, J. M. et al. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 14, 1379\u20131392 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"28653_CR28","doi-asserted-by":"publisher","first-page":"e1006846","DOI":"10.1371\/journal.pgen.1006846","volume":"13","author":"P Dietrich","year":"2017","unstructured":"Dietrich, P., Johnson, I. M., Alli, S. & Dragatsis, I. Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis. PLoS Genet. 13, e1006846 (2017).","journal-title":"PLoS Genet."},{"key":"28653_CR29","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.celrep.2019.12.069","volume":"30","author":"CJ Burrus","year":"2020","unstructured":"Burrus, C. J. et al. Striatal projection neurons require huntingtin for synaptic connectivity and survival. Cell Rep. 30, 642\u2013657 (2020). e646.","journal-title":"Cell Rep."},{"key":"28653_CR30","first-page":"3","volume":"9","author":"WF Kaemmerer","year":"2019","unstructured":"Kaemmerer, W. F. & Grondin, R. C. The effects of huntingtin-lowering: what do we know so far? Degener. Neurol. Neuromuscul. Dis. 9, 3\u201317 (2019).","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"28653_CR31","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1093\/nar\/gkw538","volume":"44","author":"S Schuierer","year":"2016","unstructured":"Schuierer, S. & Roma, G. The exon quantification pipeline (EQP): a comprehensive approach to the quantification of gene, exon and junction expression from RNA-seq data. Nucleic Acids Res. 44, e132\u2013e132 (2016).","journal-title":"Nucleic Acids Res."},{"key":"28653_CR32","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47\u2013e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"28653_CR33","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham, H. et al. Welcome to the tidyverse. J. Open Source Softw. 4, 1686 (2019).","journal-title":"J. Open Source Softw."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28653-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28653-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28653-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T11:30:04Z","timestamp":1669289404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28653-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["28653"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-28653-6","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741759479.793592088","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"assertion":[{"value":"21 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.R., B.B., C.G.K., D.T., G.R., J.H.C. J.K., M.B., M.H., N.D., N.R., R.D., R.S., T.F., T.P., and Y.S. are (or were at the time the research was conducted) employees of Novartis. B.L.D. and A.M.M. have sponsored research from Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1150"}}